ArticlePloS one2013
Selective light-triggered release of DNA from gold nanorods switches blood clotting on and off.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 32 citations in OpenAlex.
- Applications of Gold Nanoparticles in Plasmonic and Nanophotonic Biosensing.Advances in biochemical engineering/biotechnology · 2024Review
- Controlling Coagulation in Blood with Red Light.Angewandte Chemie (International ed. in English) · 2021Article
- Self-Assembled Aptamer-Nanomedicine for Targeted Chemotherapy and Gene Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2018Article
- News Feature: Cancer nanomedicine, reengineered.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Design of Potent and Controllable Anticoagulants Using DNA Aptamers and Nanostructures.Molecules (Basel, Switzerland) · 2016Article
- Molecular ping-pong Game of Life on a two-dimensional DNA origami array.Philosophical transactions. Series A, Mathematical, physical, and engineering sciences · 2015Article
- Aptamers and their applications in nanomedicine.Small (Weinheim an der Bergstrasse, Germany) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood clotting is a precise cascade engineered to form a clot with temporal and spatial control. Current control of blood clotting is achieved predominantly by anticoagulants and thus inherently one-sided. Here we use a pair of nanorods (NRs) to provide a two-way switch for the blood clotting cascade by utilizing their ability to selectively release species on their surface under two different laser excitations. We selectively trigger release of a thrombin binding aptamer from one nanorod, inhibiting blood clotting and resulting in increased clotting time. We then release the complementary DNA as an antidote from the other NR, reversing the effect of the aptamer and restoring blood clotting. Thus, the nanorod pair acts as an on/off switch. One challenge for nanobiotechnology is the bio-nano interface, where coronas of weakly adsorbed proteins can obscure biomolecular function. We exploit these adsorbed proteins to increase aptamer and antidote loading on the nanorods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.